Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138512 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,641
- Enrollment target
NCT03138512 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,641 participants.
The verdict
NCT03138512, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,641 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL ipilimumab
- DRUG nivolumab placebo
- DRUG ipilimumab placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,641 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138512
The ClinicalTrials.gov registry entry for NCT03138512 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which nivolumab is the first listed.
NCT03138512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138512 about?
NCT03138512 is a clinical study titled "A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney". The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.
What is the current status of trial NCT03138512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,641 participants. The study started on 2017-07-07. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT03138512?
The interventions under investigation include: nivolumab (BIOLOGICAL), ipilimumab (BIOLOGICAL), nivolumab placebo (DRUG), ipilimumab placebo (DRUG).
Who is sponsoring clinical trial NCT03138512?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.